WO2000054797A3 - Pharmaceutical compositions comprising tgf-beta - Google Patents

Pharmaceutical compositions comprising tgf-beta Download PDF

Info

Publication number
WO2000054797A3
WO2000054797A3 PCT/EP2000/002303 EP0002303W WO0054797A3 WO 2000054797 A3 WO2000054797 A3 WO 2000054797A3 EP 0002303 W EP0002303 W EP 0002303W WO 0054797 A3 WO0054797 A3 WO 0054797A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
beta
acetate
pharmaceutical compositions
pharmaceutical composition
Prior art date
Application number
PCT/EP2000/002303
Other languages
French (fr)
Other versions
WO2000054797A2 (en
Inventor
Tudor Arvinte
Uwe Thomas Schote
Juergen Sigg
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Tudor Arvinte
Uwe Thomas Schote
Juergen Sigg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906060.0A external-priority patent/GB9906060D0/en
Priority claimed from GBGB9908468.3A external-priority patent/GB9908468D0/en
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Tudor Arvinte, Uwe Thomas Schote, Juergen Sigg filed Critical Novartis Ag
Priority to EP00914139A priority Critical patent/EP1161257A2/en
Priority to AU35564/00A priority patent/AU3556400A/en
Priority to JP2000604870A priority patent/JP2002539172A/en
Publication of WO2000054797A2 publication Critical patent/WO2000054797A2/en
Publication of WO2000054797A3 publication Critical patent/WO2000054797A3/en
Priority to US09/953,722 priority patent/US6649168B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention provides in one aspect a pharmaceutical composition comprising TGF-beta and a water-soluble salt chosen from calcium chloride, calcium phosphate, sodium acetate, potassium acetate, lithium acetate, ammonium acetate and ammonium bicarbonate. In another aspect the present invention also provides a pharmaceutical composition comprising TGF-beta and a biodegradable carrier, wherein the biodegradable carrier is a fibrillated calcitonin.
PCT/EP2000/002303 1999-03-17 2000-03-17 Pharmaceutical compositions comprising tgf-beta WO2000054797A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00914139A EP1161257A2 (en) 1999-03-17 2000-03-17 Pharmaceutical compositions comprising tgf-beta
AU35564/00A AU3556400A (en) 1999-03-17 2000-03-17 Pharmaceutical compositions
JP2000604870A JP2002539172A (en) 1999-03-17 2000-03-17 Pharmaceutical composition containing TGF-beta
US09/953,722 US6649168B2 (en) 1999-03-17 2001-09-17 Pharmaceutical compositions comprising TGF-beta

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9906060.0 1999-03-17
GBGB9906060.0A GB9906060D0 (en) 1999-03-17 1999-03-17 Organic compounds
GBGB9908468.3A GB9908468D0 (en) 1999-04-14 1999-04-14 Organic compounds
GB9908468.3 1999-04-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/953,722 Continuation US6649168B2 (en) 1999-03-17 2001-09-17 Pharmaceutical compositions comprising TGF-beta

Publications (2)

Publication Number Publication Date
WO2000054797A2 WO2000054797A2 (en) 2000-09-21
WO2000054797A3 true WO2000054797A3 (en) 2001-01-04

Family

ID=26315282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/002303 WO2000054797A2 (en) 1999-03-17 2000-03-17 Pharmaceutical compositions comprising tgf-beta

Country Status (5)

Country Link
US (1) US6649168B2 (en)
EP (1) EP1161257A2 (en)
JP (1) JP2002539172A (en)
AU (1) AU3556400A (en)
WO (1) WO2000054797A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7419801B2 (en) 2003-08-08 2008-09-02 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
ES2396689T3 (en) 2003-12-11 2013-02-25 Isto Technologies Inc. Particle Cartilage System
US7763257B2 (en) * 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
US20060127493A1 (en) * 2004-12-09 2006-06-15 Yves Pouliot Composition for treating psoriasis
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
US8480757B2 (en) 2005-08-26 2013-07-09 Zimmer, Inc. Implants and methods for repair, replacement and treatment of disease
EP2907519A1 (en) * 2005-10-17 2015-08-19 University of the Witwatersrand, Johannesburg Osteogenic Device for Inducing Bone Formation in Clinical Contexts
GB0604964D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604966D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
WO2007113682A2 (en) * 2006-04-06 2007-10-11 Novozymes Gropep Ltd Tgf-beta pharmaceutical compositions
WO2008070902A1 (en) * 2006-12-11 2008-06-19 Novozymes Biopharma Au Limited Tgf-beta compositions for treating infertility
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
WO2008128075A1 (en) 2007-04-12 2008-10-23 Isto Technologies, Inc. Compositions and methods for tissue repair
WO2008143867A1 (en) * 2007-05-15 2008-11-27 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
PL2080528T3 (en) * 2008-01-17 2015-02-27 Cieslik Tadeusz Preparation for regeneration of postoperative and post-traumatic bone defects
US20090291113A1 (en) * 2008-04-14 2009-11-26 Adocia Osteogenic composition comprising a growth factor, a soluble cation salt and organic support
CN102065882A (en) * 2008-04-14 2011-05-18 阿道恰公司 Osteogenic composition including a complex growth factor/amphiphilic polymer, a soluble cation salt, and an organic substrate
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US11324774B2 (en) * 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
EP0325471A1 (en) * 1988-01-22 1989-07-26 Collagen Corporation Method for suppressing the growth of normal and cancer cells
JPH045965A (en) * 1990-04-24 1992-01-09 Terumo Corp Auxiliary material for fixing artificial joint or packing chipping part of bone
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
WO1994015653A1 (en) * 1993-01-12 1994-07-21 Genentech, Inc. Tgf-beta formulation for inducing bone growth

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
ATE37983T1 (en) 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
IL78197A (en) 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE60059B1 (en) 1985-04-19 1994-05-18 Oncogene Science Inc Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
NZ222168A (en) 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
GB8813033D0 (en) 1988-06-02 1988-07-06 Geistlich Soehne Ag Chemical compound
SE8804164A0 (en) 1988-11-17 1990-05-18 Per Prisell Pharmaceutical preparation
US5470829A (en) 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
US5264214A (en) 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
US5290558A (en) 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
CA2071912C (en) * 1990-11-30 2002-10-15 Hanne Bentz Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
GB9108634D0 (en) * 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5801141A (en) 1991-06-24 1998-09-01 American Cyanamid Company Implant compositions containing a biologically active protein, peptide or polypeptide
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5688765A (en) 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
CA2103943A1 (en) 1992-08-21 1994-02-22 A. Gregory Bruce Composition and methods for the generation of bone
US5817625A (en) 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
SG52402A1 (en) 1992-12-22 1998-09-28 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
AU6028094A (en) 1993-01-26 1994-08-15 Celtrix Pharmaceuticals, Inc. Compositions containing transforming growth factor beta stabilized by glycosaminoglycans
NO940913L (en) 1993-03-26 1994-09-27 Bristol Myers Squibb Co Controlled Release Preparations of Biologically Active TGF
AU6586394A (en) 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
US5451411A (en) 1993-10-15 1995-09-19 University Of Washington Methods and compositions for the oral delivery of therapeutic agents
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5626861A (en) 1994-04-01 1997-05-06 Massachusetts Institute Of Technology Polymeric-hydroxyapatite bone composite
GB9407135D0 (en) 1994-04-11 1994-06-01 Aberdeen University And Plasma Treatment of osteoporosis
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
US5614206A (en) 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
JP3843145B2 (en) 1995-12-25 2006-11-08 株式会社ルネサステクノロジ Synchronous semiconductor memory device
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
CA2268156C (en) 1996-10-16 2007-05-29 Etex Corporation Bioceramic compositions
US5756127A (en) 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
GB9623205D0 (en) 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
CN1055640C (en) 1996-11-29 2000-08-23 沃维汉 Human calcium degrading gene concerned peptide fatty composite and preparation thereof
US5866165A (en) 1997-01-15 1999-02-02 Orquest, Inc. Collagen-polysaccharide matrix for bone and cartilage repair
JP5105216B2 (en) 1997-02-13 2012-12-26 ジンマー オーソバイオロジックス，インコーポレーテッド Implantable putty-like material
WO1998035631A1 (en) 1997-02-14 1998-08-20 Pathak Chandrashekar Biocompatible polymers and methods for their use
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
DE19706667A1 (en) 1997-02-20 1998-08-27 Merck Patent Gmbh Bone replacement material with a surface covering with peptides with RGD amino acid sequence
DE19709763C2 (en) 1997-03-10 2000-10-05 Matthias Epple Process for producing porous molded articles from polyhydroxycarboxylic acid and use of the process
AU7080098A (en) 1997-04-24 1998-11-13 Takeda Chemical Industries Ltd. Apatite-coated solid composition
JP3368323B2 (en) 1997-05-14 2003-01-20 独立行政法人農業生物資源研究所 Chitin beads, chitosan beads, a method for producing these beads, a carrier comprising these beads, and a method for producing microsporidian spores
EP0896825B1 (en) 1997-08-14 2002-07-17 Sulzer Innotec Ag Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
US6296667B1 (en) 1997-10-01 2001-10-02 Phillips-Origen Ceramic Technology, Llc Bone substitutes
WO2000001410A1 (en) 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
US20040169365A1 (en) 2002-10-08 2004-09-02 Gabriella Piomboni Article in the forms of a book with a frame

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
EP0325471A1 (en) * 1988-01-22 1989-07-26 Collagen Corporation Method for suppressing the growth of normal and cancer cells
JPH045965A (en) * 1990-04-24 1992-01-09 Terumo Corp Auxiliary material for fixing artificial joint or packing chipping part of bone
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
WO1994015653A1 (en) * 1993-01-12 1994-07-21 Genentech, Inc. Tgf-beta formulation for inducing bone growth

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9230, Derwent World Patents Index; AN 060919, XP002144391, "Auxiliary material fix artificial joint or filling bone deffects-comprises biodegradable or bio-absorbable material and leaves structure to allow formation in fresh bones" *
See also references of EP1161257A2 *

Also Published As

Publication number Publication date
US6649168B2 (en) 2003-11-18
JP2002539172A (en) 2002-11-19
AU3556400A (en) 2000-10-04
US20020064516A1 (en) 2002-05-30
WO2000054797A2 (en) 2000-09-21
EP1161257A2 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
WO2000054797A3 (en) Pharmaceutical compositions comprising tgf-beta
WO2001083657A3 (en) Pouched compositions
ZA986338B (en) Simethicone/anhydrous calcium phosphate compositions.
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
AU7931301A (en) Method of using diketopiperazines and composition containing them
CA2303358A1 (en) Free-flowing fertilizer compositions
WO1999036099A8 (en) Sustained release compositions, process for producing the same and utilization thereof
EP1721838A3 (en) Kit of water-soluble or water dispersible pouches
NZ336348A (en) Solid block alkaline detergent composition comprising an alkalinity source, and a binding agent comprising an alkali metal carbonate mono hydrate and an organic sequestrant
WO2001012133A3 (en) Cosmetic compositions with self-warming component
AU2001279710A1 (en) Magnesium-ammonium-phosphate cements, the production of the same and the use thereof
WO2002007767A3 (en) Pharmaceutical suspension compositions lacking a polymeric suspending agent
WO2002005800A3 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
CA2404689A1 (en) Multi-compartment pouch comprising separate solid and liquid components
AU2001294021A1 (en) Polymeric aqueous coating compositions
WO2001060335A3 (en) Delivery systems using preformed biodegradable polymer compositions and methods
CA2355618A1 (en) Polyol/oil suspensions for the sustained release of proteins
AU2706100A (en) Polymeric compostions
EP1438967A3 (en) Pharmaceutical compositions of fibrinolytic agent
HUP0303295A3 (en) Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent
AU2963400A (en) Improved controlled release compositions and method
ZA991181B (en) Thickened emulsion compositions for use as propellants and explosives.
AU5947099A (en) Catalyst composition comprising a titanium compound, a phosphorus compound and a solubility promoter; preparation and use thereof
AU1887399A (en) Aqueous compositions comprising complexing agents and uses therof
AUPR874601A0 (en) Selective targeting of apoptotic cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000914139

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 604870

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09953722

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000914139

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642